Table 1.

Main clinical characteristics, treatment and disease course of three patients with CML and COVID-19 infection.

#	gender	age	co-morbidities	COVID symptoms	COVID category	COVID treatment	CML dg. calendar year and prognostic score	TKI	Molecular remission status at COVID	COVID outcome
1	F	88	hypertension, generalized arteriosclerosis	weakness	mild	none	2013 Sokal score 1,01 (intermediate) ELTS score 2,638 (high risk).	imatinib	MR5	recovered
2	M	43	none	weakness, sore throat, fever	mild	amoxicillin + clavulanic acid	2006 Sokal score 0,64 (low) ELTS 2,0525 (intermediate risk).	imatinib	MR4	recovered
3	M	47	NSTEMI subtotal CX occlusion, PCI in 2015	coughing, fever, diarrhoe, anosmia	mild	azithromycin	2010 Sokal score (0,66 low risk) ELTS 3,9847 (high risk).	bosutinib (fourth line)	MR4	recovered

^*COVID-19 IgG antibodies (using an Abbott SARS-CoV-2-Ig test) were found to be present in our patients 6 month, 10 weeks and 5 weeks following the COVID-19 infection, respectively. As vitamin D has been suggested to be an additional factor in improving outcomes in patients with COVID 19 infections, we also tested for 25-OH vitamin D serum levels at these time points. Serum 25-OH vitamin D levels were found to be normal in all the three patients (44.6 ng/ml, 33.5 ng/ml and 48.1 ng/ml, respectively (normal values: 30–60 ng/ml)).

^**NSTEMI: non-ST-elevation myocardial infarction. PCI: percutaneous coronary intervention. CX: circumflex artery. ELTS: EUTOS (EUropean Treatment Outcome Study) long-term survival score.